Skip to main content
. Author manuscript; available in PMC: 2020 Nov 5.
Published in final edited form as: J Immunol. 2020 Jul 20;205(4):1157–1166. doi: 10.4049/jimmunol.1901544

Figure 6.

Figure 6.

COX inhibition with flurbiprofen increased ILC2 and type 2 cytokine responses. WT BALB/c mice were treated with Indo, flurbiprofen (FBP, 75 μg/ml, B–H) or Veh in drinking water and challenged intranasally with Alt (A) once, or (B-H) daily for 4 days. Mouse lungs were harvested (A) 1 h after Alt challenge for ELISA, or (B–H) 24 h after the last Alt challenge for ELISA and flow cytometry. (A) IL-33 levels in BALF. (B)–(C) IL-5 and IL-13 levels in the lung homogenate. (D) Total numbers of live cells. (E–H) The numbers of ILC2 (Lin−CD90+KLRG1+ST2+ cells), IL-5−IL-13+ ILC2, IL-5+IL-13+ ILC2, and IL-5+IL-13− ILC2 in the lung. * p<0.05, n=5–7 mice per group.